SCHEMBL10018599

SCHEMBL10018599

Cn1cnc2c1c(=O)n(Cn1c(=O)c3c(ncn3C)n(C)c1=O)c(=O)n2C

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 9/20 0.72
BLM P54132 2/20 0.70
GLA P06280 1/20 0.70
ADORA2A P29274 3/20 0.69
ACHE P22303 2/20 0.69
PIK3CD O00329 1/20 0.69
POLB P06746 1/20 0.69
ADORA3 P0DMS8 1/20 0.69
CNR1 P21554 1/20 0.69
ADORA1 P30542 1/20 0.69
NTSR1 P30989 1/20 0.69
MC3R P41968 1/20 0.69
NOTUM Q6P988 1/20 0.69
SIRT3 Q9NTG7 1/20 0.69
GDA Q9Y2T3 1/20 0.69
NR2E1 Q9Y466 1/20 0.69
PDE4A P27815 3/20 0.63
PDE4B Q07343 3/20 0.63
PDE4C Q08493 3/20 0.63
PDE4D Q08499 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bisdionin B SCHEMBL29896692 0.91 ADORA2B (0.74) ADORA2BBLMGLAADORA2AACHE
Bisdionin D SCHEMBL16120988 0.88 ADORA2B (0.79) ADORA2BBLMGLAADORA2AACHE
Bisdionin C SCHEMBL10018600 0.88 CHIT1 (0.75) ADORA2BBLMGLAADORA2AACHE
SCHEMBL516446 0.88 ADORA2A (0.74) ADORA2BBLMGLAADORA2AACHE
SCHEMBL315740 0.87 ADORA2B (0.82) ADORA2BBLMGLAADORA2AACHE
SCHEMBL5463429 0.87 ADORA2B (0.68) ADORA2BBLMGLAADORA2AACHE
SCHEMBL29904572 0.87 ADORA2B (0.68) ADORA2BBLMGLAADORA2AACHE
SCHEMBL7384278 0.87 ADORA2B (0.68) ADORA2BBLMGLAADORA2AACHE
SCHEMBL6250731 0.87 ADORA2B (0.68) ADORA2BBLMGLAADORA2AACHE
SCHEMBL29379846 0.87 ADORA2B (0.71) ADORA2BBLMGLAADORA2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4450163-A ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) 1984-05-22 US claimed
EP-0063827-A1 1-Isopropyl- and 1-isobutyl-3,7-dimethyl xanthine as pharmaceutical preparations SOCIETE DES PRODUITS NESTLE S.A. (CH) 1982-11-03 EP claimed
US-8207175-B2 Inhibitor compounds UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-06-26 US disclosed
US-20090215798-A1 Inhibitor Compounds UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2009-08-27 US disclosed
EP-0019165-B1 PROCESS FOR PREPARING 1,3,7-TRIALKYLXANTHINES SOCIETE DES PRODUITS NESTLE S.A. (CH) 1985-07-31 EP disclosed
US-4450163-A ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) 1984-05-22 US disclosed
US-4450163-A ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) 1984-05-22 US disclosed
US-4450163-A ANTIBODY INHIBITORS; N-ALKYLATION OF XANTHINES USING PHASE TRANSFER AGENTS SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) 1984-05-22 US disclosed
EP-0063827-A1 1-Isopropyl- and 1-isobutyl-3,7-dimethyl xanthine as pharmaceutical preparations SOCIETE DES PRODUITS NESTLE S.A. (CH) 1982-11-03 EP disclosed
EP-0063827-A1 1-Isopropyl- and 1-isobutyl-3,7-dimethyl xanthine as pharmaceutical preparations SOCIETE DES PRODUITS NESTLE S.A. (CH) 1982-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215798-A1 Inhibitor Compounds ENGASE, MAN2B2, CHIA ADORA2B 4138/4885BLM 2841/4885GLA 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.